Brexit shows no signs of mercy to drugmakers

Brexit uncertainty is threatening drugmakers all over the world to invest hundreds of millions of dollars to maintain a steady supply of medicines to patients, wringing money that could have gone to developing new treatments.



Britain’s departure from the EU has forced companies including AstraZeneca Plc, GlaxoSmithKline Plc and Merck & Co. to build stockpiles of their medicines in preparation for potential shipping delays. Much of the industry can’t raise inventories because their production facilities are already at full capacity.

Brexit also threatens supplies of safe and secure medical isotopes that cannot be stockpiled because they decay quickly. According to an article in the British Medical Journal, medical isotopes are used to diagnose and treat about 1 million people in the U.K. each year. This complicates things further and eventually weaken UK’s position.

Drugmakers large and small have their hand’s full counting expenditures from Britain’s exit from the EU. GlaxoSmithKline has estimated as much as about $100 million in costs.

Pfizer said in an email that its costs stem from transferring product testing and licenses, changing clinical trial management procedures, and other preventive measures to other countries will reach $100 million.

The company is working “to meet EU legal requirements after the U.S. is no longer a member state, especially in the regulatory, manufacturing and supply chain areas,” according to a filing last month where it cited the cost estimate.

Dechra Pharmaceuticals Plc said it needs to spend $2.6 million in the event of a hard Brexit, in order to duplicate testing and move product registrations to the EU to avoid trade barriers.

Pfizer referred to Brexit as part of a challenging global economic environment in filings last year. It is pushing Britain and the EU to work out an agreement to keep their regulatory systems coordinated after the Brexit.

In addition to supply and regulatory concerns, drugmakers also face the challenge of clinical trials. Human testing of new drugs and devices in the EU must be sponsored by an entity based in the bloc, and pharmaceutical companies would need to establish new representatives in the EU for their studies.

Avatar
Anna Domanska
Anna Domanska is an Industry Leaders Magazine author possessing wide-range of knowledge for Business News. She is an avid reader and writer of Business and CEO Magazines and a rigorous follower of Business Leaders.

Recent Posts

Herman Miller acquires Knoll for $1.8 billion

Herman Miller acquires Knoll for $1.8 billion

Furniture design giant Herman Miller, Inc. announced its $1.8 billion acquisition of competitor Knoll Inc. on Monday. The acquisition comes at a time when the world is undergoing a
8 hours ago
What to expect from Apple’s Spring Loaded Event on April 20

What to expect from Apple’s Spring Loaded Event on April 20

On April 20, Apple CEO Tim Cook will take the stage to walk us down memory lane. The company’s ‘Spring Loaded’ event on Tuesday will usher in the launch of Apple’s next-gen
13 hours ago
Facebook’s Clubhouse clone to launch in summer

Facebook’s Clubhouse clone to launch in summer

Facebook Inc. on Monday announced it will launch several audio-centric products that can help it compete against Clubhouse, an audio-only chatting app that exploded in popularity d
13 hours ago
IBM revenue beats estimates, buoyed by cloud strength

IBM revenue beats estimates, buoyed by cloud strength

During IBM’s earnings call with analysts, Krishna said he knew that the January transformation in IBM’s strategy to invite more ecosystem partners would “take time for result
16 hours ago
Goldman Sachs invests $69 million in fintech Starling

Goldman Sachs invests $69 million in fintech Starling

Goldman Sachs Growth Equity has invested £50 million ($69 million) in UK digital bank, Starling. The investment is in addition to the bank’s oversubscribed £272 million Ser
1 day ago
Apple to launch hybrid TV set-top with speaker

Apple to launch hybrid TV set-top with speaker

Apple is bolstering its smart home devices space with the introduction of a new hybrid device— a combination of an Apple TV and a smart speaker with a screen, according to news r
1 day ago